Pablo Tebas
Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Department: Medicine
Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Fax: 215-349-8011
Publications
Education:
MD
Universidad Autónoma de Madrid, Spain, 1985.
MD
Universidad Autónoma de Madrid, Spain, 1985.
Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Certifications
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2014.
American Board of Internal Medicine, Infectious Diseases, 2015.
Permanent linkSpanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2014.
American Board of Internal Medicine, Infectious Diseases, 2015.
Description of Research Expertise
My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
Description of Clinical Expertise
My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of PennsylvaniaSelected Publications
Orkin, C., Mngqibisa, R., Velez, J. D., Kumar, P., Braun, D. L., Carr, A., Bloch, M., Walmsley, S., Tebas, P., Yokomaku, Y., Diamond, T. L., Jackson, B., Eves, K., Grandhi, A., Fuszard, M., Klopfer, S. O., Stamm, L. M., Fox, M. C., Kim, J.: Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet 407(10528): 599-610, March 2026.Short W.R., Scott R.K., Zimmerman M., Baron J., Momplaisir F., Patel D., Joseph N., Pierre C., Clarke D., Knapp K.M., Pagkalinawan S., Tebas P.: LA CAB/RPV in Pregnancy: Bimonthly Dosing in the Setting of Predicted Reduced RPV Exposure. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 792 February 2026.
Orkin C.M., Mngqibisa R., Velez J.D., Kumar P., Braun D., Carr A., Bloch M., Walmsley S., Tebas P., Calmy A.L., Fuszard M., Diamond T.L., Jackson B., Fox M.C., Kim J.: Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase III Study. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 515 February 2026.
Vendrame E., Fichtenbaum C.J., Osiyemi O., Wiznia A., Gupta S., Brimhall D., Morse C., Slim J., Tebas P., Liu X., Zheng Y., Chakrabarti T., Cortese M., Workowski K., Kumar P.: Safety, PK, and Pharmacodynamics of Amtabafusp, a Bispecific T-Cell Engager, in People With HIV. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 371 February 2026.
Choudhary M.C., Choi Y., Aga E., Bosch R.J., Silva de Assis T., Landais E., Reeves J.D., Petropoulos C.J., Montefiori D., Caskey M., Bar K.J., Smiley S., Tebas P.: Stable HIV-1 Autologous and Heterologous Virus Neutralization on Suppressive ART. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 301 February 2026.
Tebas P., Patel A., Agnes J., Parzych E.M., Tsang C., Morales K., Fisher P.D., Francica J.R., Humeau L., Pallesen J., Leon P., Esser M., Smith T.R.F., Weiner D.B.: Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 180 February 2026.
Cha R., Serebryannyy L., Sieczkarski S., Rupert C., Smith N.M., Venuto C.S., Ma Q., Morse G.D., Maenza J., Wagner Cardoso S., Tebas P., Mellors J.W., Belaunzaran Zamudio P., Arduino R.C., Crowell T.A.: Optimization of Dose and Analytic Treatment Interruption for VRC07-523LS and PGT121.414.LS. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 491 February 2026.
DeStefanis T., Belinky F., Ko S.H., Coates E., Strom L., Happe M., Bar K.J., Tebas P., Boritz E., Lynch R.: In Vivo Escape Pathways to VRC07-523LS and VRC01LS and Their Effects on CD4bs bNAb Susceptibility. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 578 February 2026.
Short W.R., Wessolossky M., Scott R.K., Zimmerman M., Tebas P.: Evaluating Viral Decay Kinetics of Long-Acting Cabotegravir/Rilpivirine in Pregnancy. 33nd Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 791 February 2026.
Tebas, P., Jadlowsky, J. K., Zhou, Y., Pampena, M. B., Leslie, G. J., Liu, N., Srivatsa, S., Maldini, C. R., Wang, J., Tsang, C. J., Mohamed, O., Romano, J., Haggarty, B., Plesa, G., Gaymon, A. L., Brennan, A. L., Veloso, E., Levine, B. L., Putt, M. E., Kulikovskaya, I., Gonzalez, V., Fraietta, J. A., Betts, M. R., Hoxie, J. A., Riley, J. L.: Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor. Mol Ther 34(3): 1352-1366, 2026.